Terbinafine (Lamisil)

Terbinafine is a synthetic allylamine antifungal medication used in equine medicine for the treatment of dermatophyte infections, most commonly ringworm. Marketed under the brand name Lamisil among others, terbinafine has become an important option for treating fungal skin infections in horses due to its excellent activity against the dermatophyte species responsible for most equine ringworm cases. The medication is available in both topical and oral formulations, allowing flexibility in treatment approach based on the extent and severity of infection.

The mechanism of action of terbinafine involves inhibition of squalene epoxidase, an enzyme essential for fungal ergosterol synthesis. By blocking this enzyme, terbinafine causes accumulation of squalene within fungal cells while depleting ergosterol from cell membranes. The resulting membrane instability leads to fungal cell death. This mechanism is distinct from azole antifungals, which target a different enzyme in the ergosterol pathway, making terbinafine valuable when azole resistance is present or suspected. Terbinafine is primarily fungicidal against dermatophytes, directly killing fungal organisms rather than merely inhibiting their growth.

Terbinafine is available in multiple formulations suitable for equine use. Topical preparations including creams and sprays are commonly used for localized or limited ringworm infections. These over-the-counter products are readily available and can be applied directly to affected areas. Oral terbinafine tablets are available by prescription and may be used for extensive or refractory dermatophyte infections, though oral use in horses requires careful consideration of cost, potential side effects, and pharmacokinetic factors. Your veterinarian will recommend the most appropriate formulation based on your horse's specific situation.

The safety profile of topical terbinafine is excellent, as minimal systemic absorption occurs through intact or mildly affected skin. Oral terbinafine is also generally well tolerated, though systemic administration carries greater potential for adverse effects than topical use. Veterinary guidance is important for ensuring appropriate diagnosis and treatment selection, as not all skin conditions that appear fungal are actually caused by dermatophytes. Bacterial infections, rain rot, and other conditions may mimic ringworm and require different treatment approaches.

The primary indication for terbinafine in horses is the treatment of dermatophytosis, commonly known as ringworm. This contagious fungal infection is caused by dermatophyte fungi, primarily Trichophyton and Microsporum species, and represents one of the most common skin conditions affecting horses worldwide. Ringworm typically presents as circular patches of hair loss with crusty, scaly, often gray skin surfaces. Terbinafine's potent activity against these dermatophyte organisms makes it highly effective for treating equine ringworm infections.

Terbinafine is particularly valuable for treating ringworm infections that have not responded adequately to other antifungal treatments. Some dermatophyte isolates may exhibit reduced susceptibility to azole antifungals such as miconazole or clotrimazole. In these situations, terbinafine's different mechanism of action provides an alternative approach that may succeed where other treatments have failed. The medication's fungicidal activity, directly killing fungi rather than simply inhibiting growth, may also contribute to better outcomes in stubborn infections.

For extensive ringworm infections involving large body surface areas or multiple lesions, oral terbinafine may be considered when topical therapy alone is impractical or insufficient. Systemic treatment delivers the medication throughout the body, reaching all affected areas including those difficult to access with topical products. Oral terbinafine achieves high concentrations in skin, hair follicles, and sebaceous glands, providing effective drug levels at the sites where dermatophyte organisms reside. The decision to use oral therapy requires veterinary judgment regarding the extent of infection, treatment costs, and potential for adverse effects.

Girth itch, pastern dermatitis with dermatophyte involvement, and other localized dermatophytoses represent additional indications for terbinafine therapy. These conditions may affect specific body regions and respond well to targeted topical treatment. Terbinafine cream or spray applied to affected areas can effectively address localized fungal infections while avoiding the cost and potential systemic effects of oral treatment.

While terbinafine has excellent activity against dermatophytes, it has more limited effectiveness against yeast organisms such as Candida species. For skin conditions involving yeast rather than dermatophytes, alternative antifungal agents such as nystatin or azole antifungals may be more appropriate. Proper diagnostic evaluation to identify the causative organisms helps ensure selection of the most effective antifungal therapy for each individual case.

The dosing protocol for terbinafine in horses depends on whether topical or oral therapy is selected and the extent of the fungal infection. Unlike many equine medications where dosing is precisely calculated by body weight, topical terbinafine application is based on affected surface area coverage. Oral terbinafine dosing in horses is extrapolated from human use and other species, as specific equine pharmacokinetic studies are limited. Your veterinarian will determine the most appropriate treatment approach based on your horse's individual situation.

For topical treatment of localized ringworm lesions, terbinafine cream or spray is typically applied to affected areas once or twice daily. The area should be gently cleaned before application to remove crusts, debris, and loose hair that might impede medication contact with the skin. A thin layer of cream should be applied to cover the entire lesion plus approximately one inch of surrounding apparently normal skin, as dermatophyte organisms may extend beyond visible lesion boundaries. Treatment typically continues for one to two weeks beyond apparent clinical resolution to ensure complete eradication.

Oral terbinafine dosing in horses has been extrapolated from human and small animal protocols, with typical doses ranging from approximately 5 to 10 mg/kg once daily by mouth. However, specific dosing should be determined by your veterinarian based on the individual case. Treatment duration for oral therapy is typically several weeks, as dermatophyte infections require sustained antifungal exposure for complete resolution. The tablets may be administered by dissolving in a small amount of water and syringing or by mixing with feed, though palatability issues may arise.

Environmental decontamination is an essential component of ringworm treatment regardless of which terbinafine formulation is used. Dermatophyte spores can persist in the environment for months to years, causing reinfection if not addressed. Grooming equipment, tack, blankets, stall surfaces, and anything contacting the infected horse should be cleaned and disinfected. Isolation of infected horses from susceptible herdmates reduces spread during the treatment period.

If a topical application is missed, apply terbinafine as soon as you remember and continue the regular schedule. For oral doses, administer the missed dose when remembered unless it is almost time for the next scheduled dose, in which case skip the missed dose and resume normal scheduling. Never double doses to compensate for missed administrations.

Completing the full course of treatment is essential for successful ringworm eradication. Dermatophyte organisms can persist in hair follicles and skin layers even after visible improvement. Stopping treatment when lesions first appear to resolve commonly results in recurrence as surviving organisms repopulate. Most veterinarians recommend continuing treatment for at least one to two weeks after complete clinical resolution to ensure all fungi are eliminated.

Topical terbinafine is generally very well tolerated in horses, with most animals experiencing no adverse effects from treatment. The limited systemic absorption from skin application minimizes the potential for systemic side effects. The cream and spray formulations are designed to be non-irritating and are typically comfortable for horses when applied to affected areas. The excellent local tolerability makes topical terbinafine suitable for treating even extensive ringworm lesions.

Mild local irritation at the application site represents the most commonly reported side effect of topical terbinafine. Some horses may exhibit temporary redness, itching, or mild discomfort after application. These reactions are generally self-limiting and resolve within hours. If local irritation is persistent or worsening, contact your veterinarian to discuss whether treatment modification is appropriate. In most cases, mild irritation does not necessitate discontinuing treatment.

Oral terbinafine carries a greater potential for systemic side effects compared to topical use. Gastrointestinal effects including decreased appetite, loose stool, or mild colic signs are possible with oral administration. These effects are typically mild but should be monitored. More significant concerns with oral terbinafine include potential hepatotoxicity, as the drug is metabolized by the liver. Horses receiving oral terbinafine, particularly for extended treatment courses, may benefit from baseline and periodic liver enzyme monitoring.

Hypersensitivity reactions to terbinafine, while uncommon, can occur with either topical or oral administration. Signs of allergic reaction may include increased skin irritation, hives, swelling, or systemic symptoms. Severe allergic reactions are rare but possible. If you observe signs suggestive of allergic reaction, discontinue use and contact your veterinarian promptly. Horses with known allergies to terbinafine or related allylamine antifungals should not receive these medications.

Rare side effects reported with oral terbinafine in other species include taste disturbances, visual changes, and blood dyscrasias. While these effects have not been systematically studied in horses, awareness of their possibility is appropriate when using oral terbinafine. Any unexpected changes in your horse's behavior, appetite, or general condition during oral terbinafine therapy should be reported to your veterinarian for evaluation.

The primary contraindication for terbinafine is known hypersensitivity or allergy to terbinafine or other allylamine antifungal agents. Horses that have experienced allergic reactions to terbinafine in the past should not receive this medication in any formulation. Cross-reactivity between different allylamine antifungals is possible. Always inform your veterinarian of any previous adverse reactions to antifungal medications before beginning treatment.

Hepatic impairment represents a significant contraindication for oral terbinafine use. The medication is extensively metabolized by the liver, and compromised hepatic function can lead to drug accumulation and increased toxicity risk. Horses with known liver disease or those receiving other hepatotoxic medications should not receive oral terbinafine unless the potential benefits clearly outweigh the risks and close monitoring can be provided. Topical terbinafine may be used with greater safety in these individuals due to minimal systemic absorption.

Renal impairment may also affect oral terbinafine clearance, though to a lesser degree than hepatic dysfunction. Horses with significant kidney disease should receive oral terbinafine cautiously if at all, with appropriate dose adjustment and monitoring. Again, topical therapy presents less concern in renally compromised patients due to limited systemic exposure.

Pregnancy and lactation considerations for terbinafine in horses are not well established. The medication crosses the placenta in other species and is excreted in milk. While topical use with minimal absorption is unlikely to pose significant risks, oral terbinafine should be used in pregnant or nursing mares only when clearly necessary and when potential benefits outweigh possible risks. Your veterinarian can help weigh these considerations for mares requiring antifungal therapy.

Drug interactions with topically applied terbinafine are essentially negligible due to the minimal systemic absorption that occurs from skin application. The medication acts locally at the application site without achieving significant blood concentrations. This makes topical terbinafine safe to use in horses receiving virtually any other medications without concern for systemic drug interactions.

Oral terbinafine has greater interaction potential due to its systemic absorption and hepatic metabolism. The medication is metabolized by cytochrome P450 enzymes in the liver, and drugs that inhibit or induce these enzymes may alter terbinafine blood levels. Additionally, terbinafine inhibits certain P450 enzymes and may affect metabolism of other drugs. While specific interaction studies in horses are lacking, caution is warranted when combining oral terbinafine with other hepatically metabolized medications.

Concomitant use of oral terbinafine with other potentially hepatotoxic drugs should be avoided or carefully monitored. Medications known to affect liver function may have additive hepatotoxic potential when combined with terbinafine. If oral terbinafine is necessary in a horse receiving other medications affecting liver function, more frequent liver enzyme monitoring may be appropriate.

Caffeine metabolism may be affected by terbinafine in some species, though the relevance of this interaction in horses is unclear. More clinically relevant is the potential interaction with certain medications metabolized by CYP2D6, which terbinafine inhibits. However, the specific implications of this interaction in equine patients are not well characterized due to limited pharmacokinetic research in horses.

Monitoring requirements during terbinafine treatment vary based on whether topical or oral therapy is used. For topical treatment, regular visual assessment of treated lesions for signs of healing is the primary monitoring need. Look for reduction in lesion size, decreased scaling and crusting, and regrowth of hair in affected areas. Treatment response is usually visible within one to two weeks, with continued improvement over the full treatment course.

For oral terbinafine therapy, more comprehensive monitoring is appropriate given the potential for systemic effects. Baseline liver enzyme assessment before beginning treatment provides reference values for comparison. Periodic rechecks of liver enzymes during extended oral treatment courses help detect hepatotoxicity early if it develops. Additionally, monitor for any signs of gastrointestinal upset, changes in appetite, or alterations in behavior that might indicate adverse drug effects.

Special populations requiring additional consideration include foals, geriatric horses, and those with compromised hepatic or renal function. Young horses and geriatrics may have altered drug metabolism that affects oral terbinafine handling. Horses with liver or kidney disease require careful evaluation of risk versus benefit before oral terbinafine use. In these populations, topical therapy may be preferred when feasible.

Competition horses should consider potential detection of terbinafine on drug testing when using oral formulations. While topical application results in minimal systemic absorption unlikely to cause positive tests, oral terbinafine achieves significant blood levels that may be detectable. Horse owners competing under FEI, USEF, or racing commission rules should consult current prohibited substance lists and discuss timing of treatment relative to competition with their veterinarian.

Long-term use considerations primarily apply to oral terbinafine. Extended treatment courses increase cumulative hepatic exposure and the potential for liver-related adverse effects. Monitoring of liver function becomes increasingly important with prolonged therapy. For most dermatophyte infections, treatment courses of several weeks are sufficient, and indefinite therapy is not typically required. Chronic or recurrent infections warrant investigation of underlying predisposing factors rather than ongoing antifungal treatment.

Proper storage of terbinafine products maintains medication stability and effectiveness. Both topical and oral formulations should be stored at room temperature, typically between 59°F and 86°F (15°C to 30°C). Avoid exposing the medication to extreme temperatures, humidity, or direct light. In barn environments, store terbinafine products in a climate-controlled area such as a tack room rather than in unheated or non-air-conditioned spaces where temperature fluctuations may occur.

Topical terbinafine products should be kept in their original containers with caps tightly closed when not in use. Spray formulations should be stored upright to prevent leakage. Creams should maintain a uniform consistency; separation, unusual color changes, or altered texture may indicate degradation. Protect all formulations from contamination by avoiding contact between applicators and wound surfaces or other potentially contaminated materials.

Oral terbinafine tablets should remain in their original packaging until use to protect from moisture and light. Blister packaging should not be opened until the dose is needed. Keep tablets dry and in a cool location. Tablets that have changed color, developed an unusual odor, or become soft or crumbly should not be used as these changes may indicate degradation.

Human handlers face minimal safety concerns when applying topical terbinafine to horses. The medication is well tolerated on human skin under normal conditions. However, standard hygiene practices including hand washing after application are appropriate. Individuals with known terbinafine allergies should wear gloves during application. Keep all medications out of reach of children and pets.

Draft horses and other heavy breeds do not require specific dosage adjustments for topical terbinafine since application is based on affected surface area. For oral dosing, weight-based calculations apply, but no breed-specific sensitivities have been identified. Large breeds may require substantial quantities of topical medication when treating extensive ringworm infections. Draft breeds do not appear to have increased or decreased susceptibility to dermatophyte infections compared to other horses, and standard treatment protocols apply.

Light horse breeds and warmbloods represent the typical population for terbinafine use and respond predictably to treatment. These breeds commonly encounter dermatophyte exposure in training and competition environments where horses from multiple sources interact. Performance horses should consider competition implications of oral terbinafine use, though topical application is unlikely to affect drug testing. Promptly treating ringworm in performance horses helps prevent spread to other horses in training facilities.

Ponies and miniature horses receive the same terbinafine formulations as larger breeds. Topical application amounts are adjusted based on lesion size, while oral dosing is calculated by body weight for smaller equines. Careful weight estimation is important for accurate oral dosing in smaller horses and ponies to avoid underdosing or overdosing. These smaller equines metabolize medications similarly to larger horses, and no specific dose adjustments beyond weight-based calculations are typically needed.

No breed-specific sensitivities to terbinafine have been documented in horses. The medication can be used across all breeds without genetic concerns. However, individual horses of any breed may experience hypersensitivity reactions, and any suspected allergic response should be reported to your veterinarian. Breeds with specific genetic conditions such as HYPP in Quarter Horses do not have known interactions with terbinafine, and the medication can be used safely in affected individuals.

Other antifungal agents used for dermatophyte infections in horses provide alternatives when terbinafine is not suitable. Azole antifungals including miconazole, clotrimazole, and ketoconazole have different mechanisms of action and may be effective when terbinafine is not. These medications inhibit a different enzyme in the ergosterol synthesis pathway and may succeed in cases of allylamine-resistant organisms. Topical azoles are commonly used for equine ringworm and represent first-line choices alongside terbinafine.

Griseofulvin is an older systemic antifungal that has been used for decades to treat dermatophyte infections in horses. Administered orally, griseofulvin accumulates in keratin-containing tissues including skin and hair, providing activity at sites of dermatophyte infection. While effective, griseofulvin requires extended treatment courses and has potential for adverse effects. It remains an option for severe or refractory dermatophytosis, particularly when newer agents are not available or appropriate.

Topical treatments beyond antifungals can supplement terbinafine therapy for ringworm. Antiseptic shampoos containing chlorhexidine or other antimicrobials help reduce fungal and bacterial loads on the skin. Lime sulfur dips have traditional use for dermatophyte treatment but are less commonly employed today due to odor, staining, and availability of more convenient options. These adjunctive treatments may accelerate resolution when used alongside terbinafine.

Environmental management represents an essential complement to any antifungal medication for ringworm treatment. Dermatophyte spores survive in the environment for extended periods and cause reinfection if not addressed. Thorough cleaning and disinfection of grooming equipment, tack, stall surfaces, and anything contacting infected horses prevents environmental reinfection. Quarantine of infected animals protects susceptible herdmates during treatment. Your veterinarian can provide guidance on comprehensive ringworm management incorporating both antifungal therapy and environmental control measures.